OA12624A - Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. - Google Patents

Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. Download PDF

Info

Publication number
OA12624A
OA12624A OA1200300325A OA1200300325A OA12624A OA 12624 A OA12624 A OA 12624A OA 1200300325 A OA1200300325 A OA 1200300325A OA 1200300325 A OA1200300325 A OA 1200300325A OA 12624 A OA12624 A OA 12624A
Authority
OA
OAPI
Prior art keywords
phenyl
alkyl
amino
trifluoro
propanol
Prior art date
Application number
OA1200300325A
Other languages
English (en)
Inventor
Marshall David Crew
Dwayne Thomas Friesen
Rodney James Ketner
Ravi Mysore Shanker
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12624A publication Critical patent/OA12624A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Polymerisation Methods In General (AREA)
OA1200300325A 2001-06-22 2002-05-08 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. OA12624A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30025601P 2001-06-22 2001-06-22

Publications (1)

Publication Number Publication Date
OA12624A true OA12624A (en) 2006-06-12

Family

ID=23158332

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300325A OA12624A (en) 2001-06-22 2002-05-08 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers.

Country Status (28)

Country Link
US (3) US20030054038A1 (de)
EP (1) EP1399190B1 (de)
JP (1) JP2004534822A (de)
KR (1) KR20040011549A (de)
CN (1) CN1545421A (de)
AT (1) ATE480226T1 (de)
BG (1) BG108488A (de)
BR (1) BR0210530A (de)
CA (1) CA2450762A1 (de)
CO (1) CO5540325A2 (de)
CR (1) CR7171A (de)
CZ (1) CZ20033457A3 (de)
DE (1) DE60237602D1 (de)
EA (1) EA200301250A1 (de)
EC (1) ECSP034913A (de)
EE (1) EE200400033A (de)
HU (1) HUP0400264A2 (de)
IL (1) IL158991A0 (de)
IS (1) IS7047A (de)
MA (1) MA27039A1 (de)
MX (1) MXPA03011933A (de)
NO (1) NO20035699D0 (de)
OA (1) OA12624A (de)
PL (1) PL368587A1 (de)
SK (1) SK15732003A3 (de)
TN (1) TNSN03137A1 (de)
WO (1) WO2003000292A1 (de)
ZA (1) ZA200308989B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1308228B1 (de) * 2000-08-11 2007-06-13 Ishihara Sangyo Kaisha, Ltd. Kolloidale metall-lösung, herstellungsverfahren dafür und diese lösung enthaltendes beschichtungsmaterial
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
PT1404300E (pt) * 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60331873D1 (de) * 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
WO2005004989A2 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
TW200514579A (en) 2003-07-24 2005-05-01 Smithkline Beecham Corp Orally dissolving films
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
CN1863511A (zh) * 2003-08-04 2006-11-15 辉瑞产品公司 提供控制释放的胆固醇酯转移蛋白抑制剂以及立即释放的HMG－CoA还原酶抑制剂的剂型
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2568007A1 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US20080096924A1 (en) * 2004-12-17 2008-04-24 Ono Pharmaceutical Co., Ltd. Amorphous Composition
WO2006082518A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
DE102005007059A1 (de) * 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8372836B2 (en) * 2006-10-17 2013-02-12 Bend Research, Inc. Spray dried formulation
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008098195A2 (en) * 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
GB0703627D0 (en) * 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
GB2446953A (en) * 2007-02-24 2008-08-27 Agt Sciences Ltd Aqueous pharmaceutical formulations
JP5167345B2 (ja) * 2007-05-07 2013-03-21 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤を加速放出する腸溶コーティングを含む固体剤形
WO2009022821A2 (en) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2229151B1 (de) * 2007-12-12 2012-08-08 Basf Se Salze von wirkstoffen mit polymeren gegenionen
US20100184870A1 (en) * 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
BR112012013503B8 (pt) 2009-12-03 2021-05-25 Alcon Res Llc composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade
EP2990032A1 (de) 2010-08-03 2016-03-02 G. Pohl-Boskamp GmbH & Co. KG Verwendung von glyceryltrinitrat zur behandlung traumatischer ödeme
PL2678000T3 (pl) 2011-02-25 2018-08-31 G. Pohl-Boskamp Gmbh & Co. Kg Stabilizowane granulaty zawierające triazotan glicerolu
CA2865917C (en) * 2011-03-01 2020-09-29 4413261 Canada Inc. (Spencer Canada) Two speed monolithic system for controlled release of drugs
WO2013025449A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
ES2617494T3 (es) 2012-05-31 2017-06-19 G. Pohl-Boskamp Gmbh & Co. Kg Inducción de arteriogénesis con un donador de óxido nítrico tal como nitroglicerina
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
BR112015022846A2 (pt) * 2013-03-14 2017-11-07 Shire Human Genetic Therapies uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
EP2878310B1 (de) 2013-11-29 2017-01-11 G. Pohl-Boskamp GmbH & Co. KG Sprühbare wässrige Zusammensetzung mit Nitroglycerin
JP6537147B2 (ja) * 2014-03-18 2019-07-03 武田薬品工業株式会社 固体分散体
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
WO2017223017A2 (en) * 2016-06-23 2017-12-28 Dow Global Technologies Llc Esterified cellulose ethers comprising phthalyl groups
CN109563176B (zh) * 2016-08-23 2021-09-28 陶氏环球技术有限责任公司 邻苯二甲酸乙酸纤维素醚
EP3558860A4 (de) * 2016-12-21 2020-07-29 The Coca-Cola Company Getränkespender zur ausgabe von zutaten mit niedriger löslichkeit
US10347667B2 (en) * 2017-07-26 2019-07-09 International Business Machines Corporation Thin-film negative differential resistance and neuronal circuit
WO2019193488A1 (en) 2018-04-06 2019-10-10 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
BR112021001170A2 (pt) 2018-07-30 2021-04-27 Chugai Seiyaku Kabushiki Kaisha dispersão sólida de derivado de hidantoína
CA3146466A1 (en) * 2019-08-15 2021-02-18 Warren K. Miller Ammonia as a processing aid for sprayed solid dispersions
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
WO2023086832A1 (en) * 2021-11-09 2023-05-19 Board Of Regents, The University Oftexas System Methods of preparing dosage forms using 3d printing containing amorphous solid dispersions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US103225A (en) * 1870-05-17 andrew myers
US565629A (en) * 1896-08-11 Fastener for bottles
US522520A (en) * 1894-07-03 Flower-holder for florists use
US2830987A (en) * 1958-04-15 Derivatives of phenthiazine
FR1159125A (fr) * 1953-03-27 1958-06-23 Promonta Chem Fab Procédé pour préparer des dérivés de la phényl-thiazine présentant comme substituant basique un noyau hétérocyclique contenant un atome d'azote
US2901478A (en) * 1957-02-11 1959-08-25 Promonta Chem Fab Phenothiazine compounds
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4689319A (en) * 1983-01-13 1987-08-25 Colorado State University Research Foundation Oral energy rich therapy for diarrhea in mammals
JPS59193832A (ja) 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製法
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4867970A (en) 1987-05-21 1989-09-19 E. R. Squibb & Sons, Inc. Moistureless oral drug delivery formulation and method for preparing same
US4835186A (en) 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
FR2632521B1 (fr) * 1988-06-10 1990-09-14 Rhone Poulenc Sante Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0462066A1 (de) 1990-06-15 1991-12-18 Warner-Lambert Company Amorphes Gemfibrozil
EP0580860B2 (de) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Verfahren zur herstellung einer festen dispersion
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
ES2109377T3 (es) 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
DE19637517A1 (de) * 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
WO1999027946A1 (en) * 1997-12-02 1999-06-10 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19918434A1 (de) * 1999-04-23 2000-10-26 Basf Ag Feste Pharmazeutische Formulierungen von säurelabilen Protonenpumpenblockern
KR20050049562A (ko) 1999-10-27 2005-05-25 싸이토키네틱스, 인코포레이티드 퀴나졸리논을 사용하는 방법 및 조성물
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors

Also Published As

Publication number Publication date
CN1545421A (zh) 2004-11-10
NO20035699D0 (no) 2003-12-19
ATE480226T1 (de) 2010-09-15
PL368587A1 (en) 2005-04-04
EA200301250A1 (ru) 2004-06-24
KR20040011549A (ko) 2004-02-05
WO2003000292A1 (en) 2003-01-03
TNSN03137A1 (en) 2005-12-23
ECSP034913A (es) 2004-01-28
DE60237602D1 (de) 2010-10-21
US20030054038A1 (en) 2003-03-20
HUP0400264A2 (hu) 2004-08-30
SK15732003A3 (sk) 2005-01-03
US8147872B2 (en) 2012-04-03
IL158991A0 (en) 2004-05-12
MXPA03011933A (es) 2004-03-26
BG108488A (bg) 2005-01-31
CR7171A (es) 2004-02-23
CA2450762A1 (en) 2003-01-03
CO5540325A2 (es) 2005-07-29
EP1399190B1 (de) 2010-09-08
US20060204577A1 (en) 2006-09-14
IS7047A (is) 2003-11-20
ZA200308989B (en) 2004-11-19
MA27039A1 (fr) 2004-12-20
JP2004534822A (ja) 2004-11-18
CZ20033457A3 (cs) 2004-09-15
BR0210530A (pt) 2004-06-22
US8173142B2 (en) 2012-05-08
EE200400033A (et) 2004-06-15
US20060003011A1 (en) 2006-01-05
EP1399190A1 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
OA12624A (en) Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers.
CA2448864C (en) Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
AU2002302903B9 (en) Pharmaceutical compositions of adsorbates of amorphous drug
US9468604B2 (en) Pharmaceutical compositions of dispersions of drug and neutral polymers
AU2002302903A1 (en) Pharmaceutical compositions of adsorbates of amorphous drug
CA2391078A1 (en) Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AU2002302886A1 (en) Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers